Investors in Acorda Therapeutics, Inc. (ACOR) need to pay close attention to the stock based on moves in the options market lately.
- Business Wire•3 days ago
Acorda Therapeutics, Inc. today announced that Catherine D. Strader, Ph.D., has joined its board of directors, effective February 17. Dr. Strader is currently a founding partner at Synergy Partners R&D Solutions.
- Insider Monkey•8 days ago
In order to ensure an extension of Ampyra’s protection to 2026, Acorda Therapeutics Inc (NASDAQ:ACOR) must fight off competition from competitors such as Roxane, Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA), and Mylan NV (NASDAQ:MYL) as well as ensure it keeps its patents. This is according to Michael Yee, an RBC analyst. Ten companies have been sued […]
CDG.BE : Summary for ACORDA THERAP.CDT DL-,001 - Yahoo Finance
ACORDA THERAP.CDT DL-,001 (CDG.BE)
Berlin - Berlin Delayed Price. Currency in EUR
Add to watchlist
As of 8:08AM CET. Market open.
|Bid||0.00 x 10000|
|Ask||0.00 x 10000|
|Day's Range||23.35 - 23.35|
|52 Week Range||22.32 - 23.78|
|PE Ratio (TTM)||N/A|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|